|
|
|
|
|
25.03.26 - 16:06
|
Weave Bio Establishes Inaugural Strategic Advisory Board to Shape the Future of AI-Driven Regulatory Science (Business Wire)
|
|
|
Board unites senior regulatory, quality, investment, and AI leaders from Boehringer Ingelheim, Takeda, Gilead Sciences, Serrado Capital, and Stanford UniversitySAN FRANCISCO--(BUSINESS WIRE)--$TMV #AIinPharma--Weave Bio, the leader in AI-native regulatory automation, today announced the formation of its inaugural Strategic Advisory Board (SAB). Bringing together senior executives and thought leaders with expertise spanning pharma regulatory strategy and operations, health authority policy and practice, capital markets, and academic research, the SAB will serve as a strategic forum to guide the evolution of the Weave Platform and advance the responsible adoption of AI across the life sciences regulatory ecosystem.
"Regulatory workflows are the backbone of a therapeutic candidate's success, and for too long they have been defined by manual, time-consuming processes that slow the path from discovery to patients," said Brandon Rice, Co-Founder and CEO of Weave Bio. "Our Strategic Advisory Boar...
|
|
|
|
|
24.03.26 - 08:54
|
Rights to antibody drug by China′s Keymed change hands in Gilead acquisition of Ouro (SCMP)
|
|
|
US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China's Keymed Biosciences, in a deal worth up to US$2.18 billion.
Gilead Sciences is among a group of global drug makers facing patent expirations and turning to mergers, acquisitions and licensing deals to refill their drug pipelines.
Under the agreement, Gilead Sciences would pay shareholders of US-based Ouro Medicines US$1.675 billion......
|
|
|
24.03.26 - 08:02
|
Gilead mit Doppelschlag (Der Aktionaer)
|
|
|
Zwei milliardenschwere Übernahmen in einem Monat: Die Biotech-Gesellschaft Gilead bleibt äußerst aktiv in Sachen M&A. Nachdem die Amerikaner bereits am 23. Februar die Akquisition des Partners Arcellx bekanntgaben, wurde am gestrigen Montag, also exakt einen Monat später, der geplante Zukauf von Ouro Medicines kommuniziert....
|
|
|
|
|
24.03.26 - 06:54
|
Gilead Sciences To Acquire Ouro Medicines (AFX)
|
|
|
FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD), on Monday, entered into a definitive agreement to acquire privately held Ouro Medicines.The deal includes $1.675 billion in upfront cash, with ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.03.26 - 23:18
|
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases (Business Wire)
|
|
|
-- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead's Inflammation Portfolio --
-- Gilead Intends to Enter into a Strategic Collaboration with Galapagos on the Ouro Portfolio of Medicines --FOSTER CITY, Calif.--(BUSINESS WIRE)--#GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases.
The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead's growing inflammation portfolio. OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously administered treatment course. In ongoing Phase 1/2 clinical studies, OM336 has demonstrated transformative efficacy and a differentiated safety profile after a single treatment cycle in severe antibody-mediated orphan diseases including autoimmune hemolyt...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
